Genmab A/S Announces Share Buy-back Program Transactions
Ticker: GNMSF · Form: 6-K · Filed: May 27, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | May 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, company-announcement
TL;DR
Genmab bought back shares on 5/26, part of ongoing program.
AI Summary
On May 26, 2025, Genmab A/S announced transactions related to its share buy-back program. The company purchased shares as part of this ongoing program, details of which are provided in the filing.
Why It Matters
This filing indicates Genmab is actively managing its share count, which can impact earnings per share and shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine update on a share buy-back program and does not introduce new material risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- May 26, 2025 (date) — Announcement date
- 001-38976 (other) — SEC File Number
FAQ
What is the purpose of the Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of May 2025.
What specific exhibit is included in this filing?
Exhibit 99.1 is a Company Announcement dated May 26, 2025, detailing Transactions in Connection with Share Buy-back Program.
Is Genmab A/S incorporating this report into its existing registration statements?
Yes, this report on Form 6-K is deemed to be incorporated by reference into Genmab A/S's registration statements on Form S-8.
What is the principal executive office address for Genmab A/S?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
What is the SIC code for Genmab A/S?
The Standard Industrial Classification (SIC) code for Genmab A/S is 2834, Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 27, 2025 regarding GENMAB A/S (GNMSF).